PDA Reschedules Annual Meeting Due to COVID-19
The organization is postponing its annual meeting to July 2020 because of the developing COVID-19 outbreak.
Citing the number of participants unable to travel as a result of COVID-19 outbreak, the Parenteral Drug Association (PDA) has rescheduled its annual meeting to July 20–22, 2020 in Raleigh, NC, according to a statement on the organizations website. The meeting, which was originally scheduled for March 30–April 1, will still be held in the Raleigh Convention Center.
“PDA considers safety and health of event attendees as a subject of utmost importance. This is relevant as attendees from various countries, regions, and continents will come to PDA events. The coronavirus outbreak is a global concern. Our sympathies are with those affected in China, and all around the world. We are not scheduling any activities in China for the present. We are monitoring all registrants to our events and reserve the right to restrict attendance by anyone who has recently traveled to China (or other affected areas as defined by the WHO),” PDA said in the statement.
Additionally, the 2020 PDA Pharmaceutical Manufacturing Data Science Workshop will be held July 23, 2020. The Annual Meeting Training Courses will be held July 23–24, 2020. PDA will transfer all registrations without penalty.
“We recognize the challenge this may cause, and we apologize for the inconvenience. Like you, we are trying to respond to the changing situation. We will be offering virtual attendance in the July meetings as an alternative to in-person attendance,” PDA said in the statement.
Source: PDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
